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doi:10.1016/j.ejvs.2010.04.023Abstract Objectives: To evaluate bioartificial haemodialysis access grafts in a sheep model
with respect to patency and morphology.
Material and methods: Bovine internal thoracic arteries (nZ 28) were decellularised. Four-
teen grafts (DC grafts) were directly implanted as cervical AV shunts, the remaining were
re-seeded with endothelial cells (ECs) derived from blood samples of the later ovine recipient
(EC grafts) first. Following simulated punctures and duplex ultrasound scans to determine
patency, grafts were explanted for immunohistochemical characterisation after 3 and 6
months, respectively. DC grafts underwent biomechanical testing for compliance (C), suture
retention strength (SRT), and burst pressure (BP) before (nZ 6) and after (nZ 6) implanta-
tion.
Results: Following 3 and 6 months, the majority of EC (nZ 6/6; nZ 6/7) and DC grafts (nZ 5/6;
nZ 5/7) were patent and not relevantly stenosed (peak systolic velocity: EC
graftsZ 76 cm s1 4; DC graftsZ 77 cm s1 5). Simulated haemodialysis punctures re-
vealed significantly shorter bleeding times in all bioartificial grafts than in native jugular
veins (P> 0.001). Comparing native carotid arteries with DC grafts prior to and post-
implantation, the latter differed significantly with respect to C (P> 0.001; PZ 0.005),
whereas only pre-implant DC grafts differed regarding BP (PZ 0.002); no differences werediac-, Thoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Carl-Neuberg-Str. 1,
11 532 6592; fax: þ49 511 532 5404.
mh-hannover.de (M.H. Wilhelmi).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Bioartificial Haemodialysis Access in a Sheep Model 811observed for SRT. Histology revealed complete endothelial surface coverage of EC, but not
DC grafts. Furthermore, DC grafts exhibited areas of pronounced tissue calcification.
Conclusion: The preclinical development of a bioartificial haemodialysis access graft with
promising mechanical and morphological properties in a sheep model is feasible.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The quality and performance of the vascular access is of
utmost importance for patients undergoing haemodialysis
therapy. Native arteriovenous (AV-) fistulae still represent
the ideal haemodialysis access with respect to flow rate,
durability, primary and secondary intervention rates and
the incidence of complications.1 Pisoni and co-workers
reported a primary patency rate for native fistulae of 83% in
Europe (68% in the US) and 49% for prosthetic grafts,
respectively.2 The most important disadvantages associ-
ated with native fistulae are the need for maturation
before the first puncture and a not or no longer usable
native vasculature due to diseased or exhausted vascular
sources. The advantages of synthetic grafts are large and
easily accessible surface areas for puncture manoeuvres,
short intervals until first puncture, good medical and
surgical manageability and off-the-shelf availability.
However, most important is the fact that synthetic grafts
are more often (2.5) prone to thrombosis and infections
than native AV fistulae.3e5 These factors lead to enormous
frustrations and financial burden. Thus, the aim of this
study was the preclinical evaluation of bioartificial grafts
made from xenogenic bovine internal thoracic arteries
either decellularised or re-seeded with endothelial cells
(ECs) derived from peripheral blood of the later recipient.
Analysed parameters comprised patency and macro- and
micro-structure.
Material and methods
Bovine internal thoracic arteries (ITA; nZ 28)were obtained
from a local slaughterhouse. Immediately after harvest,
arteries were incubated in 0.5% sodium dodecylsulphate,
0.5% sodium deoxycholate and DNAse 40 Uml1 (Sigma
Aldrich) for removal of cellular components. To assure
complete cellular elimination and to warrant structural
integrity of the remaining scaffold, haematoxylin and eosin
(H&E) as well as anti-Perlecan-stains (Perlecan is the major
component of the basement membrane, heparan sulphate
proteoglycan 2; anti-Perlecan, Acris antibodies) and DNA gel
electrophoreses were performed. Fourteen of the resulting
acellular grafts (DC grafts) were directly implanted between
the carotid artery and the external jugular vein in sheep,
while the remainder underwent endothelial re-seeding prior
to implantation (EC grafts; nZ 14) (Tables 1A and B).
ECs for re-seeding purposes were differentiated in vitro
from mononuclear cells (MNC) obtained from a single 50 ml
blood specimen of the prospective ovine recipients of the
EC grafts (nZ 14). MNC were isolated via Ficoll gradient
(Biocoll, Biochrom, Cambridge, UK) centrifugation (800 g,
30 min), washed (phosphate-buffered saline (PBS)), resus-
pended (EBM-2 with 2% FBS, 1% penicillin/streptamycin)
and subsequently seeded on gelatine-coated culture flasks
for further endothelial differentiation. The medium waschanged every third day and cells were separated after
reaching confluence (every 5e7 days). The (endothelial)
phenotype of putative endothelial precursor cells (EPC) was
verified immunohistologically via anti-CD31 stain (AbD
Serotec) and Dil-Ac-LDL uptake assays (AlexaFluor488
conjugated, Sanbio, Mountainview, CA, USA). EC desig-
nated for re-seeding were assessed by immunostaining
against von Willebrand Factor (vWF, Dako, Glostrup,
Denmark), endothelial nitric oxide synthase (eNOS, BD
Biosciences, Sparks, MD, USA) and CD31 (AbD Serotec).
All matrix re-seeding steps were performed in a specially
designedbioreactor systemallowing for graft rotation aswell
as pulsed and continuous medium flow conditions as
described previously.6 In brief, a single graft (length: 80 mm;
diameter: 5 mm) was inserted into a bioreactor chamber.
Following two initial seeding steps (750 000 cells cm2,
administered on day 1 and day 2) with very low rotational
speed (1.5 rpm) and no flow through the chamber, flow
characteristics (day 3: laminar; thereafter pulsatile) and
pressure were increased stepwise and continued for 10 days.
The medium was changed every third day. To assess the
degree of endothelial surface coverage, small tissue samples
taken at both ends of the graft were analysed by scanning
electron microscopy (SEM) immediately after removal from
the bioreactor and prior to implantation.
Following in vitro processing (decellularisationZ DC
grafts; decellularisationþ EC re-seedingZ EC grafts),
grafts (length: w75 mm, diameter: w5 mm) were implan-
ted subcutaneously as right cervical AV fistulae, connecting
the carotid artery and the external jugular vein
(‘Schwarzkopf’ sheep, total nZ 28). Anastomoses (w2.5
larger than the graft diameter) were performed in standard
end-to-side, running suture technique using polypropylene
6/0 (Ethicon, Somerville, NJ, USA). A single bolus of 100 U
heparin per kg bodyweight was administered IV before
clamping. Thereafter, no further anticoagulants were
administered. After 10 initial postoperative days at the
Animal Research Facility of Hannover Medical School, all
animals were moved to an off-side indoor housing facility
until graft explantation. All animal experiments were per-
formed under general anaesthesia (induced with 30 mg kg1
ketamine, and maintained with an IV bolus injection of
2 mg kg1 propofol). For pain control, animals received
4 mg kg1 Carprofen (Pfizer, New York City, NY, USA) intra-
operatively and on days 1 and 3, thereafter as necessary.
The study protocol was approved by the local authorities
(Niedersaechsisches Landesamt fuer Verbraucherschutz
und Lebensmittelsicherheit) and all sheep received care in
compliance with the ‘Guide for the Care and Use of Labo-
ratory Animals’ (Washington DC: National Academy Press;
1996 www.nap.edu/catalog/5140.html).
Colour duplex ultrasound scans (LOGIQ Book-XP,
General Electric, Fairfield, CT, USA) were performed to
Table 1A Duplex sonographic analyses and graft punctures.
Sheep no. Graft no. Study time Patency Diameter (cm) PSV (cm s1) BT (min)
Pre-OP 3-Months 6-Months 3-Months 6-Months Graft Vein
1 DC-1 3 Months Yes 0.5 0.48 e 55.37 e 5 6
2 DC-2 3 Months Yes 0.5 0.52 e 64.05 e 5 6
3 DC-3 3 Months Occluded 0.5 n.d. e n.d. e n.d. n.d.
4 DC-4 3 Months Yes 0.5 0.62 e 96.07 e 5 6
5 DC-5 3 Months Yes 0.6 0.58 e 29.11 e 5 6
6 DC-6 3 Months Yes 0.6 0.72 e 133.92 e 5 6
Mean (SD) or % 83.3 0.5 (0.1) 0.6 (0.1) e 75.7 (40.4) e 5 (0) 6 (0)
7 DC-7 6 Months Yes 0.6 e 0.65 e 76.67 5 6
8 DC-8 6 Months Yes 0.6 e 0.55 e 157.21 5 6
9 DC-9 6 Months Occluded 0.6 e n.d. e n.d. n.d. n.d.
10 DC-10 6 Months Dead* 0.6 e n.d. e n.d. n.d. n.d.
11 DC-11 6 Months Yes 0.5 e 0.4 e 18.92 5 6
12 DC-12 6 Months Occluded 0.5 e n.d. e n.d. n.d. n.d.
13 DC-13 6 Months Yes 0.5 e 0.5 e 62.11 5 6
14 DC-14 6 Months Yes 0.5 e n.d.* e n.d.* 5 7
Mean (SD) or % 71.43 0.6 (0.1) 0.5 (0.1) e 78.7 (57.8) 5 (0) 6.2 (0.45)
15 EC-1 3 Months Yes 0.5 0.45 e 38.82 e 6 8
16 EC-2 3 Months Yes 0.6 n.d.** e n.d.** e 6 8
17 EC-3 3 Months Yes 0.5 0.52 e 31.05 e 6 6
18 EC-4 3 Months Yes 0.5 0.54 e 29.11 e 5 6
19 EC-5 3 Months Yes 0.5 0.62 e 96.07 e 5 7
20 EC-6 3 Months Yes 0.6 0.72 e 133.92 e 5 5
Mean (SD) or % 100 0.5 (0.1) 0.6 (0.1) e 65.8 (47.0) e 5.5 (0.55) 6.67 (1.12)
21 EC-7 6 Months Yes 0.5 e 0.6 e 124.2 5 5
22 EC-8 6 Months Yes 0.5 e 0.69 e 72.28 5 5
23 EC-9 6 Months Occluded 0.6 e n.d. e n.d. n.d. n.d.
24 EC-10 6 Months Yes 0.6 e 0,62 e 124.85 5 6
25 EC-11 6 Months Yes 0.5 e 0.33 e 69.87 5 6
26 EC-12 6 Months Yes 0.5 e 0.5 e 56.87 5 6
27 EC-13 6 Months Dead* 0.5 e n.d. e n.d. 5 6
28 EC-14 6 Months Yes 0.6 e 0.56 e 56.11 5 6
Mean (SD) or % 85.71 0.5 (0.1) e 0.6 (0.1) e 84.0 (32) 5 (0) 5.7 (0.49)
PSV: peak systolic velocity; BT: bleeding times following graft puncture with 17G needle; vein: graft accompanying and thus, arterialized
jugular vein; DC: decellularised graft; EC: endothelial re-seeded graft; n.d.: not determined due to graft occlusion; dead*: group size
calculation corrected for dead animals; n.d.**: not determined due to technical problems; BP: burst pressure; SRT: suture retention
strength; C: circumferential compliance; NA: native ovine carotid artery.
812 S. Koenneker et al.determine patency, blood flow velocity, graft diameter
and structural alterations immediately prior to explanta-
tion. Furthermore, simulated haemodialysis-puncturing
manoeuvres were performed to assess haemostatic prop-
erties of the grafts. Practically, following complete
surgical exposure and IV administration of heparin
(100 U kg1), all grafts and the accompanying native
jugular veins were punctured at three randomly chosen
sites with standard haemodialysis cannulas (17G), which
were left in place for 15 min. After removal, a dry gauze
compress was applied to the puncture side for 5 min. If
bleeding continued, the gauze was applied again and
removed every additional minute to determine bleeding
time. Thereafter, all animals were sacrificed and grafts
were harvested for (immuno-)histological (H&E, von
Kossa, vWF, CD31, eNOS, 40,6-diamidino-2-phenylindole
(DAPI) and CD11b staining) and biomechanical evaluation.To exclusively evaluate biomechanical properties of the
decellularised matrix and the influence of in vivo remodel-
ling processes DC grafts (that is, cell free), prior to implan-
tation (nZ 6) and following 3 months of in vivo maturation
(nZ 6)were analysed andexemplarily comparedwith native
ovine carotid arteries (nZ 6). Burst pressure (BP) experi-
ments were performed by fixing a portion (w2 cm2) of each
graft inside a custom-designed burst chamber device.
A syringe pump (B. Braun, Melsungen, Germany) was pro-
grammed to force PBS on each specimen at a flow rate of
3 ml min1, and the induced pressure was detected using an
online custom-made pressure monitor system (pressure
sensor: xtrans, CODAN pvb Critical Care GmbH, Germany;
data acquisition unit: modified LabView application,
National Instruments, Munich, Germany). BP was defined as
the highest pressure value measured before structural
failure. Suture retention strength (SRT) was measured using
Table 1B Biomechanical testings.
Sheep no. Graft no. BP (mmHg) SRT (N/mm2) C (%/mmHg)
Pre-OP 3-Months Pre-OP 3-Months Pre-OP 3-Months
1 NA-1 2356 e 333.1 e 0.0168 e
2 NA-2 2432 e 389.5 e 0.0346 e
3 NA-3 3116 e 113.9 e 0.0225 e
4 NA-4 2486 e 104.1 e 0.0307 e
5 NA-5 2794 e n.d.** e 0.0227 e
6 NA-6 n.d.** e n.d.** e n.d.** e
Mean (SD) or % 2636.8 (315.39) e 235.15 (147.53) e 0.025 (0.007) e
1 DC-1 1976 1900 162,8 260.5 0.007 0.0078
2 DC-2 n.d.** 1520 n.d.** 189.8 n.d.** 0.0146
3 DC-3 1292 n.d. 245.6 n.d. 0.0061 n.d.
4 DC-4 1520 4028 117.3 138.7 0.006 0.0119
5 DC-5 1623 2493 182.4 238.7 0.0065 0.022
6 DC-6 1563 2489 168.2 204.7 0.0071 0.0159
Mean (SD) or % 1594.8 (247.19) 2486.0 (955.82) 175.26 (46.27) 206.48 (46.99) 0.0065 (0.001) 0.0144 (0.005)
PSV: peak systolic velocity; BT: bleeding times following graft puncture with 17G needle; vein: graft accompanying and thus, arterialized
jugular vein; DC: decellularised graft; EC: endothelial re-seeded graft; n.d.: not determined due to graft occlusion; dead*: group size
calculation corrected for dead animals; n.d.**: not determined due to technical problems; BP: burst pressure; SRT: suture retention
strength; C: circumferential compliance; NA: native ovine carotid artery.
Bioartificial Haemodialysis Access in a Sheep Model 813a mechanical tester (Z2.3, Zwick/Roell, Ulm, Germany) and
4/0 prolene suture material (Ethicon, Hamburg, Germany)
set 5 mm from the specimen’s edge with a cross head speed
of 30 mmmin1 at room temperature. Tensile forces were
applied until complete rupture. The compliance (C ) was
calculated based on measurements made in a custom-made
chamber fabricated of transparent poly(methlymethacry-
late) (PMMA) to enable the measurement of the vascular
grafts diameter with an optical micrometer (LS-7030(M),
Keyence, Neu-Isenburg, Germany). A pulsatile, physiological
pressure was applied and measured with a standard blood
pressure monitoring system (Xtrans, Codan pvb Medical
GmbH, Lensahn, Germany). All the datawere collected using
a Data Acquisition System (NI USB 6009, National Instru-
ments) and were monitored by means of a LabVIEW 7.1
(National Instruments) application thatwasdevelopedbyour
group. For calculation of compliance the relative volume
change was used, here expressed as relative change of the
diameter of the vessel:
CZ

Vsys  Vdia

Vdia
Psys Pdia Z

D2sys D2dia
.
D2dia
Psys  Pdia ð1Þ
Formula (1): Formula for the calculation of the compliance
(C: compliance, V: volume, D: diameter and P: pressure,
indices ‘sys’ and ‘dia’ represent systolic and diastolic
phase, respectively).
All statistical analyses of this study were performed with
SPSS for Mac, Version 17.0 (SPSS Inc, Chicago, IL, USA).
Mean and standard deviation (SD) were calculated for all
continuous values obtained in this study (diameter, peak
systolic velocity, BP, SRT, bleeding times and compliance).
One-way analysis of variance (ANOVA) was used for
comparison between groups. Differences were considered
as significant at P 0.05.Results
Decellularisation
Matrix analyses performed to assure successful matrix
decellularisation verified complete removal of all cellular-
and DNA-components. Furthermore, the integrity of the
matrix and particularly of the basement membrane could
be preserved (Fig. 1(A) and (B)).
Cell processing, characterisation and seeding
Mononuclear cells isolated from peripheral blood revealed
a slow initial growth tendency, which then increased
markedly after the first passage. Microscopic analyses dis-
played dense monolayers of cobblestone-like colonies, and
thus morphologies suggestive of the presence of ECs.
Further immunohistological characterisation of these cells
verified their mononuclear cell origin (DilAc-LDL uptake)
and, subsequent endothelial differentiation (immunostains
against vWF, CD31 and eNOS), respectively (Fig. 1(C) and
(D)). Following in vitro seeding and conditioning of cell-
matrix constructs, SEM and light microscopic analyses
revealed complete endothelial cell coverage of every graft
prior to implantation.
Animal experiments
Two sheep scheduled for an observational period of 6
months (1 DC and 1 EC grafts) died due to severe hae-
morrhage following accidental neck trauma at the fence 4
and 8 weeks after implantation, respectively. Thus, six
animals of each 3-month group and seven of each 6-month
group remained for further evaluation, respectively. Colour
duplex ultrasound scans performed immediately prior to
Figure 1 Histological and duplex analysis. (A) Native bovine internal thoracic artery (ITA) with endothelial monolayer on the
luminal surface and compact three-layered matrix organisation, H&E (200); (B) ITA following in vitro decellularisation (ZDC
graft). The basement membrane is clearly visible and appears as a thin bright line, DAPI/perlecan (200); (C) culture of ovine
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Bioartificial Haemodialysis Access in a Sheep Model 815explantation revealed that 6/6 and 6/7 of the EC grafts and
5/6 and 5/7 of the DC grafts were patent after 3 and 6
months, respectively (Tables 1A and B). None of the patent
grafts of either group revealed relevant stenosis (>30%) in
ultrasound duplex scanning and measured by PSV,
morphological alterations, significant dilatations or other
pathological changes. Mean PSV was between 69 cm s1 and
84 cm s1 and did not significantly differ between 3 and 6
months in DC and EC groups (Tables 1A and B, Fig. 1(E)e(G),
Fig. 2).
Following simulated haemodialysis-puncturing manoeu-
vres performed 3 and 6 months after graft implantation,
bleeding stopped significantly earlier in DC and EC grafts
than in respective corresponding native jugular veins.
Values for DC versus EC grafts did not significantly differ
(PZ 0.09) (Tables 1A and B, Fig. 2).
Histological and SEM analyses revealed complete luminal
surface coverage with ECs in control carotid arteries and all
EC grafts whereas only small strips of ECs restricted to
anastomotic areas were detected in DC grafts. Following 3
months, vasa vasorum were observed within the vascular
wall of all grafts regardless their type. Furthermore, areas
of pronounced tissue calcification were found throughout
the whole wall of DC grafts, whereas only tiny little spots
were observed in EC grafts (Fig. 1(H)e(L)). Up to 6 months
following implantation and independently from the type of
graft, mild accumulations of leucocyte infiltrations could
be observed in all anastomotic regions.
Biomechanical properties
Comparing native carotid arteries and DC grafts, no
differences were obtained regarding SRT, neither prior nor
post-implantation. With respect to compliance, DC grafts
prior (PZ 7.7 E5) and post-implantation (PZ 0.005)
significantly differed from native ovine arteries, whereas
only pre-implant DC grafts significantly differed regarding
BP (PZ 0.002) (Tables 1A and B, Fig. 2).
Discussion
Herein, the development of tissue-engineered vascular
access grafts made from decellularised bovine ITA and
autologous endothelial cells and its implantation in a sheep
model is described. Thebovine ITA that servedasmatrix basis
for the grafts belongs to the elastic type of arteries and is
readily available in good quantity. It was particularly chosen
because of its adequate dimensions regarding the desired
length (z15 cm) and diameter (z5 mm) of a haemodialysismononuclear cells (MNC) immediately after isolation, DilAc-LDL
differentiation of mononuclear cells, anti-eNOS/DAPI (200); (Ee
months after implantation: (E) arterial anastomosis side without vi
patent vessel graft (PSZ 92 cm s1); (H) EC graft following 6 mon
CD31/DAPI (200); (I) DC graft following 6 months in vivo with end
CD31/DAPI (400); (J) DC graft following 3 months in vivo with ne
(400); (K) mid section of a re-seeded graft following 6 months i
orientation in flow direction; (L) mid section of a decellularised g
detectable.fistula and its constitutive mechanical properties, which, in
contrast to native venous fistulae, do not require prolonged
periods of maturation.
Decellularisation was complete and ITAs remained
competent with regard to matrix integrity and particu-
larly the preservation of the basement membrane. These
features represent important prerequisites for graft
incorporation, in vitro as well as in vivo cellular repo-
pulation and therefore adequate biomechanical proper-
ties.7 Biomechanical analyses performed immediately
after in vitro generation as well as following 3 months of
in vivo maturation revealed excellent biomechanical
properties regarding the most relevant clinical and
surgical parameters, that is, burst pressure, SRT and the
circumferential compliance (C ). Needle stick injuries and
arterialisation of fistulae often result in thrombus
formation, degenerative and structural changes including
stenosis, occlusion, matrix calcification and aneurysm
formation.8e10 With respect to the resistance towards
repeated puncture, and thus, the use in haemodialysis
therapy, comparative measurements of bleeding times in
native jugular veins and grafts proved that graft puncture
sites were blood tight even earlier in DC and EC grafts.
These results as well as the absence of graft dilatation
over time underscore that both the EC and DC grafts
offer structural advantageous stability for haemodialysis
therapy.
The vast majority of endothelial cell re-seeded (EC),
as well as decellularised (DC) grafts was patent and
revealed no relevant stenosis (>30%) during the obser-
vation period up to 6 months. Intimal hyperplasia was
very limited in DC as well as in EC grafts. Nevertheless,
the in vitro re-endothelialisation of luminal surfaces prior
to implantation (EC grafts) seems to be protective against
calcification and thus, might be essential for preventing
early graft degeneration. Furthermore, as shown by mild
formation of scar tissue as well as newly generated vasa
vasorum, DC and EC grafts were rapidly integrated into
the surrounding tissue. Mild leucocyte invasion indicates
some degree of inflammatory tissue reaction. However,
these cellular responses were restricted to anastomotic
areas (arterial and venous) and no thickening of the
vascular wall was found.
The relative resistance of biological vessels against
infections is based on the presence of vasa vasorum, which
allow immunocompetent cells to reach all areas within the
vascular wall. As shown in the current study, even decellu-
larised grafts were re-vascularised within a 3-month period.
These findings may have a positive impact on infection
resistance of DC and EC grafts. However, as mentioneduptake (200); (D) cell culture following further endothelial
G) exemplary duplex ultrasound scan of a re-seeded graft 6
sible stenosis; (F) colour duplex ultrasound; (G) Doppler mode:
ths in vivo with complete endothelial surface coverage, anti-
othelial cells exclusively restricted to anastomotic areas, anti-
wly formed vasa vasroum within the vascular wall, anti-CD31/
n vivo, SEM (80): closed endothelial monolayer with cellular
raft following 6 months in vivo, SEM (81): endothelial cells
Figure 2 Statistical analysis. The bars indicate groups that were compared. The corresponding P value is presented. NA: native
ovine carotid artery; vein: jugular vein; DC graft: decellularised graft; EC graft: endothelial cell re-seeded graft; BP: burst pres-
sure; SRT: suture retention strength; C: circumferential compliance; BT: bleeding time following puncture with 17G needle;
diameter: vascular diameter; PSV: peak systolic velocity.
816 S. Koenneker et al.above, spots of pronounced calcification within the vascular
wall of decellularised grafts may point to processes of tissue
degeneration and graft protection induced by luminal
endothelial cell coverage, respectively. However, although
no major inflammatory reactions could be observed during
the study period of up to 6months, further studies addressing
the influence of potential immunological processes on the
long-term should be initiated.
Regarding the surgical and medical manageability of the
grafts, we noticed that the consistence of decellularised
(DC) grafts as well as endothelial re-seeded (EC) grafts is
very similar to that of a native artery.
In summary, wedemonstrated the successful development
of a bioartificial vessel graft re-seeded with autologous
endothelial cells obtained fromblood of theprospective ovine
recipient. It was integrated into the surrounding tissue and
exhibited promising biomechanical, structural and functional
properties in the ovine model. In the near future, we will
transfer the concept to human cells and GMP standards.
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